Cover Image

Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Hala Bekhit, Louay Eldeeb, Emad Moussa, Sarah H. Youssef, Nesreen Ali
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Hematological Oncology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Update on Biology and Treatment
by: Peter Borchmann, et al.
Published: (2025)

Long‐Term Real‐World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results
by: Prokop Vodicka, et al.
Published: (2025)

Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience
by: Vittorio Ruggero Zilioli, et al.
Published: (2024)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
by: J.T. Jutzi, et al.
Published: (2025)

International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
by: Youwen Zhu, et al.
Published: (2026)

PET2‐Adapted Therapy in Patients With Advanced‐Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater
by: Antonio Pinto, et al.
Published: (2024)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
by: Juliette Penichoux, et al.
Published: (2025)

Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma—A Regression Analysis of Dose‐Response
by: Lotte Nygård, et al.
Published: (2025)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
by: Minna Harmanen, et al.
Published: (2025)

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi‐Omic Analysis
by: Juan Quarroz Braghini, et al.
Published: (2025)

Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi‐Center Real‐Life Study
by: M. Picardi, et al.
Published: (2024)

Long‐Term Outcomes of Reduced‐Toxicity Conditioning Using 8‐Gray Total Body Irradiation, Fludarabine, and Cyclophosphamide in Children, Adolescents, and Young Adults With Hematological Malignancies
by: Hirokazu Morokawa, et al.
Published: (2024)

Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China
by: Jiajie He, et al.
Published: (2026)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
by: Francesca Maria Quaglia, et al.
Published: (2026)

A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
by: Masahito Tokunaga, et al.
Published: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Published: (2026)

Peripheral T‐Cell Lymphoma: What's Next?
by: Sang Eun Yoon, et al.
Published: (2025)

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
by: Caroline Le Lan, et al.
Published: (2024)

Routine Monitoring of CAR‐T‐Cells Expansion and Persistence in Patients With Aggressive Large B‐Cell Lymphoma by Flow Cytometry: A Single‐Center Experience
by: Alexandra Zduniak, et al.
Published: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Published: (2025)

Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
by: Robin Noel, et al.
Published: (2025)

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis
by: Oskar Steinbrecher, et al.
Published: (2024)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
by: Rui Sun, et al.
Published: (2026)

Re: Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
by: Theodoros P. Vassilakopoulos, et al.
Published: (2025)

Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
by: M. Delia, et al.
Published: (2025)

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects
by: Emil Kumar, et al.
Published: (2025)

Lomustine, Etoposide and Cyclophosphamide as Conditioning for Auto‐HCT in Lymphomas
by: Rafaella Cabral Samico, et al.
Published: (2025)

Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma
by: Hazim S. Ababneh, et al.
Published: (2024)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
by: Giacomo Loseto, et al.
Published: (2025)

Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection
by: Yue Zhao, et al.
Published: (2025)

Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches
by: Sonali M. Smith
Published: (2025)

Discovery Science highlights from the 17th International Conference on Malignant Lymphoma
by: Gabriela Forestieri, et al.
Published: (2024)

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
by: Simone Ferrero, et al.
Published: (2025)

Knockdown of VDAC1 Promotes Ferroptosis in Diffuse Large B‐Cell Lymphoma
by: Chuanming Lin, et al.
Published: (2025)

Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow‐Up of a Multicenter, Retrospective Real‐World Experience With 321 Cases Outside of Controlled Clinical Trials
Published: (2025)

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement
by: Elisabetta M. Abenavoli, et al.
Published: (2024)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
by: Meirav Kedmi, et al.
Published: (2024)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
by: Monia Marchetti, et al.
Published: (2025)

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
by: Allison M. Bock, et al.
Published: (2024)

Combining Total Metabolic Tumor Volume With Beta‐2‐Microglobulin Levels Predicts Outcomes in High‐Burden Follicular Lymphoma Patients
by: A. Zduniak, et al.
Published: (2024)